# US 2012/0252772 A1 · Cucurbitane-Triterpenoid Compounds, Pharmaceutical Composition, Use and Preparation Method Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252772 A1
- Document ID: US20120252772A1
- Status: Published application
- Kind: A1
- Application number: 13/173,200
- Filed: 2011-06-30
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: National Taiwan University
- Inventors: CHING-JANG HUANG; YUEH-HSIUNG KUO; CHIN HSU
- Web page: https://patentgrep.com/patent/US20120252772A1

## CPC

- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 36/42: Cucurbitaceae (Cucumber family)
- A61P 5/24: of the sex hormones
- A61P 5/30: Oestrogens
- A61P 15/12: for climacteric disorders
- C07J 71/0005: {Oxygen-containing hetero ring}
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a cucurbitane-triterpenoid compound for activating estrogen receptor activity, and a pharmaceutical composition, use and preparation method thereof. The cucurbitane-triterpenoid compound is presented as formula (I): wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8 and C9, R2 is carbonyl group (—C═O), methyl hydroxyl group (—CH(OH)), methyl ketone or methyl dimethoxy group (—CH(OCH3)2); and wherein while R1 is oxygen (—O—) and R2 is carbonyl group (—C═O) or methyl hydroxyl group (—CH(OH)), a single bond is formed between R1 (—O—) and C19 of R2 such that R1 and R2 are formed tetrahydro-2H-pyran-2-one or hemiacetal ring.

## Claims

### Claim 1

A cucurbitane-triterpenoid compound having the formula (I):
wherein a single bond or a double bond is formed between C5 and C10, and a single bond or a double bond is fromed between C8 and C9; when a single bond is formed between C5 and C10, the R1 is oxygen; while a single bond is formed between C8 and C9, R2 is carbonyl group (—C═O), methyl hydroxyl group (—CH(OH)), methyl ketone or methyl dimethoxy group (—CH(OCH3)2); and wherein while R1 is oxygen (—O—) and R2 is carbonyl group (—C═O) or methyl hydroxyl group (—CH(OH)), a single bond is formed between R1 (—O—) and C19 of R2 such that R1 and R2 are formed tetrahydro-2H-pyran-2-one or hemiacetal ring.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is cucurbita-6,22(E), 24-trien-3β-ol-19,5β-olide (compound 1), 5β,19-epoxycucurbita-6,22(E),24-trien-3β,19-diol (compound 2), 3β-hydroxycucurbita-5(10),6,22(E),24-tetraen-19-al (compound 3), 19-dimethoxycucurbita-5(10),6,22(E),24-tetraen-3β-ol (compound 4) or 19-nor-cucurbita-5(10),6,8,22(E),24-pentaen-3β-ol (compound 5).

### Claim 3

A method for regulation of estrogen receptor activity, comprising administering a cucurbitane-triterpenoid compound of group 1 or group 2 to a subject, wherein the group 1 is consisted of cucurbita-6,22(E),24-trien-3β-ol-19,5β-olide (compound 1), 5β,19-epoxycucurbita-6,22(E),24-trien-3β,19-diol (compound 2), 19-nor-cucurbita-5(10),6,8,22(E),24-pentaen-3β-ol (compound 5) and 5β,19-epoxycucurtita-6,24-diene-3β,23ξ-diol (compound 6); and
the group 2 is consisted of cucurbita-6,22(E),24-trien-3β-ol-19,5β-olide (compound 1), 5β,19-epoxycucurbita-6,22(E),24-trien-3β,19-diol (compound 2), 3β-hydroxycucurbita-5(10),6,22(E),24-tetraen-19-al (compound 3), 19-nor-cucurbita-5(10),6,8,22(E),24-pentaen-3β-ol (compound 5) and 5β,19-epoxycucurtita-6,24-diene-3β,23ξ-diol (compound 6); and when the cucurbitane-triterpenoid compound of the group 1 activates an estrogen receptor activity independently, whereas the cucurbitane-triterpenoid compound of the group 2 partly inhibits the estrogen receptor activity induced by endogenous estrogen.

### Claim 4 (depends on 3)

The method of claim 3, wherein the estrogen receptor is human estrogen receptor a or human estrogen receptor β.

### Claim 5 (depends on 3)

The method of claim 3, wherein the cucurbitane-triterpenoid compound is co-administered with an estrogen active compound to a subject.

### Claim 6 (depends on 3)

The method of claim 3, wherein the cucurbitane-triterpenoid compound is isolated from Momordica charantia.

### Claim 7

A pharmaceutical composition for regulation of estrogen receptor activity, comprising a group 1 or a group 2, wherein the group 1 is consisted of cucurbita-6,22(E),24-trien-3β-ol-19,5β-olide (compound 1), 5β,19-epoxycucurbita-6,22(E),24-trien-3β,19-diol (compound 2), 19-nor-cucurbita-5 (10),6,8,22(E),24-pentaen-3β-ol (compound 5) and 5β,19-epoxycucurtita-6,24-diene-3β,23ξ-diol (compound 6); and
the group 2 is consisted of cucurbita-6,22(E),24-trien-3β-ol-19,5β-olide (compound 1), 5β,19-epoxycucurbita-6,22(E),24-trien-3β,19-diol (compound 2), 3β-hydroxycucurbita-5(10),6,22(E),24-tetraen-19-al (compound 3), 19-nor-cucurbita-5(10),6,8,22(E),24-pentaen-3β-ol (compound 5), 5β,19-epoxycucurtita-6,24-diene-3β,23ξ-diol (compound 6), combinations or pharmaceutically acceptable salts thereof; and a diluent, an excipient or a carrier.

### Claim 8 (depends on 1)

A method for preparing the cucurbitane-triterpenoid compound of formula I from Momordica charantia of claim 1, comprising steps of:
(a) extracting a pre-determined weight of Momordica charantia freeze dry powder with ethyl acetate at room temperature, evaporating by reduced pressure to remove ethyl acetate and obtaining an ethyl acetate extract and a residue;
(b) extracting the residue with ethanol at room temperature, evaporating by reduced pressure to remove ethanol and obtaining an ethanol extract;
(c) separating the ethanol extract with reverse phase column chromatography having coarse particle to obtain fraction 1, acid hydrolyzing the fraction 1 and extracting with ethyl acetate at room temperature, evaporating by reduced pressure to remove solvents and obtaining an acid hydrolysate;
(d) separating the acid hydrolysate with reverse phase column chromatography to obtain fraction 2; and
(e) purifying the fraction 2 of step (d) by using reverse phase and normal phase preparative HPLC to obtain the cucurbitane-triterpenoid compound with estrogenic activity.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Momordica charantia freeze dry powder is extracted with twenty volumes of ethyl acetate in the step (a).

### Claim 10 (depends on 8)

The method of claim 8, wherein the residue is extracted with twenty volumes of ethanol in the step (b).

### Claim 11 (depends on 8)

The method of claim 8, wherein the ethanol extract is eluted by reverse phase column in the order with water, 50% methanol/water, 100% methanol and acetone as mobile phase in the step (c).

### Claim 12 (depends on 8)

The method of claim 8, wherein the ethanol extract is eluted with 80% methanol/water, followed by water, 50% methanol/water, 100% methanol and acetone to obtain and acid hydrolyze the fraction 1 in the step (c).

### Claim 13 (depends on 8)

The method of claim 8, wherein the fraction 1 is acid hydrolyzed with hydrogen chloride in the step (c).

### Claim 14 (depends on 8)

The method of claim 8, wherein the acid hydrolysate is eluted by reverse phase column in order with 80% methanol/water and 100% methanol as mobile phase in the step (d).

### Claim 15 (depends on 8)

The method of claim 8, wherein the fraction 2 is either eluted by the reverse phase preparative HPLC with 100% methanol or 100% methanol with 0.1% acetic acid as mobile phase, or the fraction 2 is eluted by normal phase HPLC with ethyl acetate/n-hexane with ratio of 3:7 or THF/n-hexane with ratio of 2:8 in the step (e).
